NCT04202965Phase 2Completed

PTG-300 in Subjects With Hereditary Hemochromatosis

Study sponsor: Protagonist Therapeutics, Inc. · PTGX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-10-06Actual

Enrollment · participants16Actual

Source updated2025-08-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Hereditary Hemochromatosis

Treatments or interventions studied

PTG-300DrugAlso known as Rusfertide

Primary outcomes · main study measures

Read the study measures

measure: Effect of PTG-300 on Transferrin Saturation; description: Change from Baseline to Week 24 (or End of Treatment) in transferrin saturation (TSAT) as measured by blood laboratory tests.; timeFrame: Week 24 (or End of Treatment if treated for less than 24 weeks); measure: Effect of PTG-300 on Serum Iron; description: Change from Baseline to Week 24 (or End of Treatment) in serum iron as measured by blood laboratory tests.; timeFrame: Week 24 (or End of Treatment if treated for less than 24 weeks)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history